▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Amy Ho

amyfaithho

Medical provider. Emergency medicine. Interest in biotech. Background in online retail.

Recent Articles by Amy Ho

May 10, 2014 by Amy Ho

Will New Regulations on E-Cigs Hurt Big Tobacco?

New regulatory proposals on tobacco questionable on both passage and impact

Apr 24, 2014 by Amy Ho

Sarepta's Still a Gamble, Even With FDA Reversal

Will Sarepta finally get approval for eteplirsen?

Apr 15, 2014 by Amy Ho

Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for Hep C Combo?

Merck plays catch-up while Bristol-Myers looks global.

Apr 4, 2014 by Amy Ho

What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?

Two drugs are hot on Pfizer’s tail.

Apr 3, 2014 by Amy Ho

Does Amgen Have the Next Lipitor on Its Hands?

Amgen leads the PCSK9-blocker class of cholesterol drugs.

Mar 31, 2014 by Amy Ho

FDA Review Incoming: Will Mannkind Finally Succeed?

Could a third rejection may be looming for MNKD inhalable insulin?

Mar 18, 2014 by Amy Ho

Trouble Ahead for Gilead and Sovaldi?

Idenix files suit atop $9 billion sales estimates for Gilead's Sovaldi

Mar 11, 2014 by Amy Ho

How Will This Latest Setback Affect Eli Lilly?

Concerns over Boerhringer Ingelheim plant delay approval of key diabetes agent

Mar 7, 2014 by Amy Ho

Cancer Immunotherapy Race Stays Unpredictable

Merck, Bristol-Myers and Roche head the race to pioneer PD-1 therapies.

Mar 4, 2014 by Amy Ho

Is This Drug Enough To Revive Hope in Eli Lilly's Pipeline?

Eli Lilly struggles to gain approval and regain diabetes market share.

Mar 4, 2014 by Amy Ho

Why Would Roche Return to the Antibiotics Market?

Roche’s new deal with Discuva marks major private sector commitment to antibiotic development

Mar 3, 2014 by Amy Ho

Bristol-Myers Closing in on Gilead in Hepatitis C Race

New breakthrough designation could help Bristol-Myers compete more quickly with market-leader Gilead.

Feb 11, 2014 by Amy Ho

Gilead Combination Hepatitis C Filing Solidifies Its Leadership

AbbVie and Bristol-Myers unlikely to catch Gilead in race for oral hep C combination therapy

Feb 11, 2014 by Amy Ho

AstraZeneca Struggles to Meet Expectations

CEO Pascal Soriot is fighting an uphill battling winning investors on pipeline.

Feb 11, 2014 by Amy Ho

Antidepressant R&D Takes Another Hit with J&J

Multiple approaches to depression treatment fail trials

Feb 4, 2014 by Amy Ho

Companies Limp Towards a Duchenne Treatment – Is There Hope of a Finish Line?

2014 starts a dismal year for Duchenne prospects by Sarepta, Prosensa, PTC and Retrophin

Feb 4, 2014 by Amy Ho

AbbVie's Challenge to Gilead in Hepatitis C Therapies

New clinical data from AbbVie spice up hepatitis C market and prospects for the company

Feb 2, 2014 by Amy Ho

Could Ariad Be Set for a Comeback?

Ariad's troubled drug Iclusig undergoes an official return to market.

Feb 2, 2014 by Amy Ho

Fierce Competition in the Diabetes Drug Market

GSK, Eli Lilly and Sanofi fight for already-crowded diabetes market share

Jan 27, 2014 by Amy Ho

Roche's Schizophrenia Drug Fails Phase III Trials, but Is Not Yet Scrapped

Well-diversified and restructured Roche handles a minor bitopertin setback.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services